The community-based, Phase 3b randomized, open-label, multicenter UPFRONT trial presented at the 53rd American Society of Hematology Annual Meeting and Exposition has found that three bortezomib-based regimens followed by weekly bortezomib maintenance therapy produced similar overall response rates (ORR), progression-free survival (PFS), and 1-year overall survival (OS) in elderly, newly diagnosed, transplant-ineligible multiple myeloma (MM) patients.
Your search for Warfarin returned 3 results
Bortezomib-Based Regimens Similarly Efficacious in Elderly, Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Patients
New recommendations are indicated for the treatment of extracranial carotid and vertebral artery disease (ECVD), UA/NSTEMI, and hypertrophic cardiomyopathy (HCM), according to several researchers who discussed the recent 2011 changes to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines at a symposium during ACC.11, the American College of Cardiology’s 60th Scientific Session.
Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.